– Late-breaking data from a head-to-head study
evaluating SKYRIZI®
(risankizumab) versus STELARA® (ustekinumab)
in moderate to severe Crohn's disease will be presented
–
Analyses on clinical and endoscopic outcomes from
AbbVie's maintenance trials for SKYRIZI® (risankizumab)
and RINVOQ® (upadacitinib) in moderate to severe Crohn's
disease and for RINVOQ in moderate to severe ulcerative
colitis
– Primary efficacy and safety results from
the Phase 3 INSPIRE induction study for risankizumab in ulcerative
colitis will be presented
– A total of 23
abstracts, including a late-breaker, with 11 oral presentations,
reinforce AbbVie's commitment to research into advancing standards
of care for people living with inflammatory bowel diseases
(IBD)
NORTH
CHICAGO, Ill., Oct. 10,
2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will
share new data from its robust gastroenterology portfolio at the
United European Gastroenterology (UEG) Week 2023 Congress taking
place in Copenhagen, Denmark from
October 14-17. AbbVie will showcase a
total of 23 abstracts, including a late-breaker, with 11 oral
presentations and 12 poster presentations spanning research on
risankizumab (SKYRIZI®) and upadacitinib
(RINVOQ®) in both Crohn's disease (CD) and ulcerative
colitis (UC).
"Our continued commitment to research in IBD demonstrates our
relentless quest to elevating standards of care for those living
with disruptive gastroenterological conditions," said Sofie Berg, PharmD, Ph.D., head of
gastroenterology, global medical affairs, AbbVie. "We look forward
to convening with the IBD community at UEG Week once again to share
recent findings from our IBD portfolio and also learning more about
the recent progress across the field."
Key data presentations will include:
- Research highlighting endoscopic outcomes with SKYRIZI and
RINVOQ for CD:
- LB01: Risankizumab versus ustekinumab for patients with
moderate to severe Crohn's disease: results from the phase
3b SEQUENCE study; Sunday, October 15, 17:00-17:12 CEST
- OP100: Maintenance of clinical, endoscopic, and
biomarker improvements with upadacitinib in patients with
moderately to severely active Crohn's disease: a post hoc analysis
of the phase 3 U-ENDURE study; Monday,
October 16, 15:06-15:18
CEST
- Insights on long-term use with RINVOQ for UC:
- PP0853: Achievement of long-term treatment goals
with upadacitinib in patients with moderately to severely active
ulcerative colitis: a post-hoc analysis of induction and
maintenance phase 3 trials; Sunday,
October 15, 10:00
CEST
- OP149: Efficacy and safety of upadacitinib after 2 years
of treatment in patients with moderately to severely active
ulcerative colitis: interim results from the phase 3 open-label
extension study (U-ACTIVATE); Tuesday,
October 17, 08:54-09:06
CEST
- Primary efficacy and safety results from the Phase 3 induction
study for risankizumab in UC:
- OP021: Risankizumab induction therapy in patients with
moderately to severely active ulcerative colitis: efficacy and
safety in the randomized phase 3 INSPIRE study; Sunday, October 15, 17:48-18:00 CEST
The full scientific program for the UEG 2023 is
available here.
"Recently, there have been many positive strides made in the IBD
treatment landscape. However, those suffering with IBD are still
experiencing unpredictable flare-ups and ongoing unresolved
inflammation," said Remo Panaccione,
MD, professor of medicine and director of the IBD unit,
University of Calgary. "The research
that will be presented by AbbVie at UEG Week 2023 will advance
knowledge to better address how new therapies may further benefit
patients with these challenging conditions with the aim to maximize
clinical and endoscopic outcomes."
The use of risankizumab is investigational in ulcerative
colitis.
SKYRIZI® (risankizumab) is part of a collaboration
between Boehringer Ingelheim and AbbVie, with AbbVie leading
development and commercialization globally.
About Crohn's Disease
Crohn's disease is a chronic,
systemic disease that manifests as inflammation within the
gastrointestinal tract, causing persistent diarrhea and abdominal
pain.1,2 It is a progressive disease, meaning it gets
worse over time in a substantial proportion of patients or may
develop complications that require urgent medical care, including
surgery.1,2 Because the signs and symptoms of Crohn's
disease are unpredictable, it causes a significant burden on people
living with the disease—not only physically, but also emotionally
and economically.1
About Ulcerative Colitis
Ulcerative colitis is a
chronic, idiopathic, immune-mediated inflammatory bowel disease
(IBD) of the large intestine that causes continuous mucosal
inflammation extending, to a variable extent, from the rectum to
the more proximal colon.3,4 The hallmark signs and
symptoms of ulcerative colitis include rectal bleeding, abdominal
pain, bloody diarrhea, tenesmus (a sense of pressure), urgency and
fecal incontinence.3,4 The disease course of ulcerative
colitis varies between patients and can range from quiescent
disease to chronic refractory disease, which in some cases can lead
to surgery or life-threatening complications.5,6 The
severity of symptoms and unpredictability of disease course can
lead to substantial burden and often disability among those living
with the disease.7
About Risankizumab (SKYRIZI®)
SKYRIZI is an
interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by
binding to its p19 subunit.8 IL-23, a cytokine involved
in inflammatory processes, is thought to be linked to a number of
chronic immune-mediated diseases.9 SKYRIZI is approved
by the U.S. Food and Drug Administration (FDA) and the European
Medicines Agency for the treatment of plaque psoriasis, psoriatic
arthritis and Crohn's disease. Phase 3 trials of risankizumab in
psoriasis, psoriatic arthritis, Crohn's disease and ulcerative
colitis are ongoing.9-11
U.S. Indications and Important Safety Information about
SKYRIZI® (risankizumab-rzaa)12
SKYRIZI
is a prescription medicine used to treat adults with:
- moderate to severe plaque psoriasis who may benefit from taking
injections or pills (systemic therapy) or treatment using
ultraviolet or UV light (phototherapy).
- active psoriatic arthritis (PsA).
- moderate to severe Crohn's disease.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about
SKYRIZI® (risankizumab-rzaa)?
SKYRIZI
is a prescription medicine that may cause serious side effects,
including:
Serious allergic reactions:
- Stop using SKYRIZI and get emergency medical help right
away if you get any of the following symptoms of a serious allergic
reaction:
– fainting, dizziness, feeling lightheaded
(low blood pressure)
– swelling of your face, eyelids, lips, mouth, tongue, or
throat
– trouble breathing or throat tightness
– chest tightness
– skin rash, hives
– itching
Infections:
SKYRIZI may lower the ability of your
immune system to fight infections and may increase your risk of
infections. Your healthcare provider should check you for
infections and tuberculosis (TB) before starting treatment with
SKYRIZI and may treat you for TB before you begin treatment with
SKYRIZI if you have a history of TB or have active TB. Your
healthcare provider should watch you closely for signs and symptoms
of TB during and after treatment with SKYRIZI.
- Tell your healthcare provider right away if you have an
infection or have symptoms of an infection, including:
– fever, sweats, or chills
– cough
– shortness of breath
– blood in your mucus (phlegm)
– muscle aches
– warm, red, or painful skin or sores on your body different from
your psoriasis
– weight loss
– diarrhea or stomach pain
– burning when you urinate or urinating more often than normal
Do not use SKYRIZI if you are allergic to
risankizumab-rzaa or any of the ingredients in SKYRIZI. See the
Medication Guide or Consumer Brief Summary for a complete list of
ingredients.
Before using SKYRIZI, tell your healthcare provider about all
of your medical conditions,
including if you:
- have any of the conditions or symptoms listed in the section
"What is the most important information I should know about
SKYRIZI?"
- have an infection that does not go away or that keeps coming
back.
- have TB or have been in close contact with someone with
TB.
- have recently received or are scheduled to receive an
immunization (vaccine). Medicines that interact with the immune
system may increase your risk of getting an infection after
receiving live vaccines. You should avoid receiving live vaccines
right before, during, or right after treatment with SKYRIZI. Tell
your healthcare provider that you are taking SKYRIZI before
receiving a vaccine.
- are pregnant or plan to become pregnant. It is not known if
SKYRIZI can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if
SKYRIZI passes into your breast milk.
- become pregnant while taking SKYRIZI. You are encouraged to
enroll in the Pregnancy Registry, which is used to collect
information about the health of you and your baby. Talk to your
healthcare provider or call 1-877-302-2161 to enroll in this
registry.
Tell your healthcare provider about all the medicines you
take, including prescription and over-the-counter medicines,
vitamins, and herbal supplements.
What are the possible side effects
of SKYRIZI?
SKYRIZI may cause serious side effects.
See "What is the most important information I should know about
SKYRIZI?"
Liver problems in Crohn's disease: A person with Crohn's
disease who received SKYRIZI through a vein in the arm developed
changes in liver blood tests with a rash that led to
hospitalization. Your healthcare provider will do blood tests to
check your liver before, during, and up to 12 weeks of treatment
and may stop treatment with SKYRIZI if you develop liver problems.
Tell your healthcare provider right away if you notice any of the
following symptoms: unexplained rash, nausea, vomiting, stomach
(abdominal) pain, tiredness (fatigue), loss of appetite, yellowing
of the skin and eyes (jaundice), and dark urine.
The most common side effects of SKYRIZI in people treated for
Crohn's disease include: upper respiratory infections,
headache, joint pain, stomach (abdominal) pain, injection site
reactions, low red blood cells (anemia), fever, back pain, and
urinary tract infection.
The most common side effects of SKYRIZI in people treated for
plaque psoriasis and psoriatic arthritis include: upper
respiratory infections, headache, feeling tired, injection site
reactions, and fungal skin infections.
These are not all the possible side effects of SKYRIZI. Call
your doctor for medical advice about
side effects.
Use SKYRIZI exactly as your healthcare provider tells you to use
it.
SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, a
600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or
360 mg/2.4 mL single-dose prefilled cartridge with on-body
injector.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit
http://www.fda.gov/medwatch or call
1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie
may be able to help. Visit
AbbVie.com/myAbbVieAssist to learn more.
Please click here for Full Prescribing
Information and Medication Guide for
SKYRIZI.
Globally, prescribing information varies; refer to the
individual country product label for complete information.
About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a
selective JAK inhibitor that is being studied in several
immune-mediated inflammatory diseases.13 Based on
enzymatic and cellular assays, RINVOQ demonstrated greater
inhibitory potency for JAK-1 and JAK-2 relative to JAK-3, and
TYK-2. The relevance of inhibition of specific JAK enzymes to
therapeutic effectiveness and safety is not currently
known.14
Phase 3 trials of RINVOQ in rheumatoid arthritis, atopic
dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's
disease, ulcerative colitis, giant cell arteritis, Takayasu
arteritis, and systemic juvenile idiopathic arthritis are
ongoing.15-23
RINVOQ (upadacitinib) U.S. Uses and Important
Safety Information14
RINVOQ is a prescription medicine used to treat:
- Adults with moderate to severe rheumatoid arthritis
(RA) when 1 or more medicines called tumor necrosis factor
(TNF) blockers have been used, and did not work well or could not
be tolerated.
- Adults with active psoriatic arthritis (PsA) when 1
or more medicines called TNF blockers have been used, and did not
work well or could not be tolerated.
- Adults with active ankylosing spondylitis (AS) when
1 or more medicines called TNF blockers have been used, and did not
work well or could not be tolerated.
- Adults with active non-radiographic axial spondyloarthritis
(nr-axSpA) with objective signs of inflammation when a TNF
blocker medicine has been used, and did not work well or could not
be tolerated.
- Adults with moderate to severe ulcerative colitis
(UC) when 1 or more medicines called TNF blockers have
been used, and did not work well or could not be tolerated.
- Adults with moderate to severe Crohn's disease
(CD) when 1 or more medicines called TNF blockers have
been used, and did not work well or could not be tolerated.
It is not known if RINVOQ is safe and effective in children with
juvenile idiopathic arthritis, psoriatic arthritis, ankylosing
spondylitis, non-radiographic axial spondyloarthritis, ulcerative
colitis, or Crohn's disease.
- Adults and children 12 years of age and older with moderate
to severe eczema (atopic dermatitis [AD]) that did not
respond to previous treatment and their eczema is not well
controlled with other pills or injections, including biologic
medicines, or the use of other pills or injections is not
recommended.
RINVOQ is safe and effective in children 12 years of age and
older weighing at least 88 pounds (40 kg) with atopic
dermatitis.
It is not known if RINVOQ is safe and effective in children
under 12 years of age with atopic dermatitis.
What is the most important information I should know about
RINVOQ?
RINVOQ may cause serious side effects, including:
- Serious infections. RINVOQ can lower your ability
to fight infections. Serious infections have happened while taking
RINVOQ, including tuberculosis (TB) and infections caused by
bacteria, fungi, or viruses that can spread throughout the body.
Some people have died from these infections. Your healthcare
provider (HCP) should test you for TB before starting RINVOQ and
check you closely for signs and symptoms of TB during treatment
with RINVOQ. You should not start taking RINVOQ if you have any
kind of infection unless your HCP tells you it is okay. If you get
a serious infection, your HCP may stop your treatment until your
infection is controlled. You may be at higher risk of developing
shingles (herpes zoster).
- Increased risk of death in people 50 years and older who
have at least 1 heart disease (cardiovascular) risk
factor.
- Cancer and immune system problems. RINVOQ may
increase your risk of certain cancers. Lymphoma and other cancers,
including skin cancers, can happen. Current or past smokers are at
higher risk of certain cancers, including lymphoma and lung cancer.
Follow your HCP's advice about having your skin checked for skin
cancer during treatment with RINVOQ. Limit the amount of time you
spend in sunlight. Wear protective clothing when you are in the sun
and use sunscreen.
- Increased risk of major cardiovascular (CV) events, such as
heart attack, stroke, or death, in people 50 years and older who
have at least 1 heart disease (CV) risk factor, especially if you
are a current or past smoker.
- Blood clots: Blood clots in the veins of the legs
or lungs and arteries can happen with RINVOQ. This may be
life-threatening and cause death. Blood clots in the veins of the
legs and lungs have happened more often in people who are 50 years
and older and with at least 1 heart disease (CV) risk factor.
- Allergic reactions. Symptoms such as rash (hives),
trouble breathing, feeling faint or dizzy, or swelling of your
lips, tongue, or throat, that may mean you are having an allergic
reaction have been seen in people taking RINVOQ. Some of these
reactions were serious. If any of these symptoms occur during
treatment with RINVOQ, stop taking RINVOQ and get emergency medical
help right away.
- Tears in the stomach or intestines. This happens
most often in people who take nonsteroidal anti-inflammatory drugs
(NSAIDs) or corticosteroids. Get medical help right away if you get
stomach-area pain, fever, chills, nausea, or vomiting.
- Changes in certain laboratory tests. Your HCP
should do blood tests before you start taking RINVOQ and while you
take it. Your HCP may stop your RINVOQ treatment for a period of
time if needed because of changes in these blood test results.
Do not take RINVOQ if you are allergic to upadacitinib or any
of the ingredients in RINVOQ. See the Medication Guide or
Consumer Brief Summary for a complete list of ingredients.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
- Are being treated for an infection, have an infection that
won't go away or keeps coming back, or have symptoms of an
infection such as:
-
- Fever, sweating, or chills
- Shortness of breath
- Warm, red, or painful skin or sores on your body
- Muscle aches
- Feeling tired
- Blood in phlegm
- Diarrhea or stomach pain
- Cough
- Weight loss
- Burning when urinating or urinating more often than normal
- Have TB or have been in close contact with someone with
TB.
- Are a current or past smoker.
- Have had a heart attack, other heart problems, or stroke.
- Have had any type of cancer, hepatitis B or C, shingles (herpes
zoster), blood clots in the veins of your legs or lungs,
diverticulitis (inflammation in parts of the large intestine), or
ulcers in your stomach or intestines.
- Have other medical conditions including liver problems, low red
or white blood cell counts, diabetes, chronic lung disease, HIV, or
a weak immune system.
- Live, have lived, or have traveled to parts of the country,
such as the Ohio and Mississippi River valleys and the
Southwest, that increase your risk of getting certain kinds of
fungal infections. If you are unsure if you've been to these types
of areas, ask your HCP.
- Have recently received or are scheduled to receive a vaccine.
People who take RINVOQ should not receive live vaccines.
- Are pregnant or plan to become pregnant. Based on findings in
animal studies, RINVOQ may harm your unborn baby. Your HCP will
check whether or not you are pregnant before you start RINVOQ. You
should use effective birth control (contraception) to avoid
becoming pregnant during treatment with RINVOQ and for 4 weeks
after your last dose.
- There is a pregnancy surveillance program for RINVOQ. The
purpose of the program is to collect information about the health
of you and your baby. If you become pregnant while taking RINVOQ,
you are encouraged to report the pregnancy by calling
1-800-633-9110.
- Are breastfeeding or plan to breastfeed. RINVOQ may pass into
your breast milk. Do not breastfeed during treatment with RINVOQ
and for 6 days after your last dose.
Tell your HCP about all the medicines you
take, including prescription and over-the-counter
medicines, vitamins, and herbal supplements. RINVOQ and other
medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
- Medicines for fungal or bacterial infections
- Rifampicin or phenytoin
- Medicines that affect your immune system
If you are not sure if you are taking any of these medicines,
ask your HCP or pharmacist.
What should I avoid while taking RINVOQ?
Avoid food or drink containing grapefruit during treatment with
RINVOQ as it may increase the risk of side effects.
What should I do or tell my HCP AFTER starting
RINVOQ?
- Tell your HCP right away if you have any symptoms of an
infection. RINVOQ can make you more likely to get infections or
make any infections you have worse.
- Get emergency help right away if you have any symptoms of a
heart attack or stroke while taking RINVOQ, including:
-
- Discomfort in the center of your chest that lasts for more than
a few minutes or that goes away and comes back
- Severe tightness, pain, pressure, or heaviness in your chest,
throat, neck, or jaw
- Pain or discomfort in your arms, back, neck, jaw, or
stomach
- Shortness of breath with or without chest discomfort
- Breaking out in a cold sweat
- Nausea or vomiting
- Feeling lightheaded
- Weakness in one part or on one side of your body
- Slurred speech
- Tell your HCP right away if you have any signs or symptoms of
blood clots during treatment with RINVOQ, including:
-
- Swelling
- Pain or tenderness in one or both legs
- Sudden unexplained chest or upper back pain
- Shortness of breath or difficulty breathing
- Tell your HCP right away if you have a fever or stomach-area
pain that does not go away, and a change in your bowel habits.
What are other possible side effects of
RINVOQ?
Common side effects include upper respiratory tract infections
(common cold, sinus infections), shingles (herpes zoster), herpes
simplex virus infections (including cold sores), bronchitis,
nausea, cough, fever, acne, headache, increased blood levels of
creatine phosphokinase, allergic reactions, inflammation of hair
follicles, stomach-area (abdominal) pain, increased weight, flu,
tiredness, lower number of certain types of white blood cells
(neutropenia, lymphopenia, leukopenia), muscle pain, flu-like
illness, rash, increased blood cholesterol levels, increased
liver enzyme levels, pneumonia, low number of red blood cells
(anemia), and infection of the stomach and intestine
(gastroenteritis).
A separation or tear to the lining of the back part of the eye
(retinal detachment) has happened in people with atopic dermatitis
treated with RINVOQ. Call your HCP right away if you have any
sudden changes in your vision during treatment with RINVOQ.
Some people taking RINVOQ may see medicine residue (a whole
tablet or tablet pieces) in their stool. If this happens, call your
healthcare provider.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ?
RINVOQ is taken once a day with or without food. Do not split,
crush, or chew the tablet. Take RINVOQ exactly as your HCP tells
you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg
extended-release tablets.
This is the most important information to know about RINVOQ.
For more information, talk to your HCP.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or
call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie
may be able to help. Visit AbbVie.com/myAbbVieAssist to
learn more.
Please click here for the Full Prescribing
Information and Medication Guide.
Globally, prescribing information varies; refer to the
individual country product label for complete information.
About AbbVie in Gastroenterology
With a robust
clinical trial program, AbbVie is committed to cutting-edge
research to drive exciting developments in inflammatory bowel
diseases (IBD), like ulcerative colitis and Crohn's disease. By
innovating, learning and adapting, AbbVie aspires to eliminate the
burden of IBD and make a positive long-term impact on the lives of
people with IBD. For more information on AbbVie in
gastroenterology, visit
https://www.abbvie.com/our-science/therapeutic-focus-areas/immunology/immunology-focus-areas/gastroenterology.html.
About AbbVie
AbbVie's mission is to discover and
deliver innovative medicines and solutions that solve serious
health issues today and address the medical challenges of tomorrow.
We strive to have a remarkable impact on people's lives across
several key therapeutic areas – immunology, oncology, neuroscience,
and eye care – and products and services in our Allergan Aesthetics
portfolio. For more information about AbbVie, please visit us at
www.abbvie.com. Follow @abbvie on X (formerly
Twitter) Facebook, Instagram, YouTube and
LinkedIn.
Forward-Looking Statements
Some statements in this
news release are, or may be considered, forward-looking statements
for purposes of the Private Securities Litigation Reform Act of
1995. The words "believe," "expect," "anticipate," "project" and
similar expressions and uses of future or conditional verbs,
generally identify forward-looking statements. AbbVie cautions that
these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those expressed or implied in the forward-looking statements.
Such risks and uncertainties include, but are not limited to,
challenges to intellectual property, competition from other
products, difficulties inherent in the research and development
process, adverse litigation or government action, and changes to
laws and regulations applicable to our industry. Additional
information about the economic, competitive, governmental,
technological and other factors that may affect AbbVie's operations
is set forth in Item 1A, "Risk Factors," of AbbVie's 2022 Annual
Report on Form 10-K, which has been filed with the Securities and
Exchange Commission, as updated by its subsequent Quarterly Reports
on Form 10-Q. AbbVie undertakes no obligation, and specifically
declines, to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except
as required by law.
References:
- Crohn's disease. Symptoms and Causes. Mayo Clinic. Available
at:
https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304.
- The Facts about Inflammatory Bowel Diseases. Crohn's &
Colitis Foundation of America. 2014. Available at:
https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf.
- Gajendran M, Loganathan P, Jimenez G, et al. A comprehensive
review and update on ulcerative colitis. Dis Mon.
2019;65(12):100851. doi:10.1016/j.disamonth.2019.02.004
- The facts about inflammatory bowel diseases. Crohn's &
Colitis Foundation of America. Accessed September 26, 2023.
https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf
- Ulcerative colitis. Mayo Clinic. Accessed September 26,
2023. https://www.mayoclinic.org/diseases-conditions/ulcerative-colitis/symptoms-causes/syc-20353326
- Surgery for Crohn's Disease and Ulcerative Colitis.
Crohn's & Colitis Foundation of America. Accessed September 26, 2023.
https://www.crohnscolitisfoundation.org/sites/default/files/legacy/assets/pdfs/surgery_brochure_final.pdf
- Mehta F. Report: economic implications of inflammatory bowel
disease and its management. Am J Manag Care. 2016;22(3
Suppl):s51-60.
- Duvallet E., Sererano L., Assier E., et al. Interleukin-23: a
key cytokine in inflammatory diseases. Ann Med. 2011. Nov
43(7):503-11.
- Pipeline – Our Science | AbbVie. AbbVie. 2021. Available
at: https://www.abbvie.com/our-science/pipeline.html. Accessed on
September 26, 2023.
- A study comparing risankizumab to placebo in participants
with active psoriatic arthritis including those who have a history
of inadequate response or intolerance to biologic therapy(ies)
(KEEPsAKE2). ClinicalTrials.gov. Updated February 28, 2023. Accessed September 26, 2023.
https://clinicaltrials.gov/ct2/show/NCT03671148
- A multicenter, randomized, double-blind, placebo
controlled induction study to evaluate the efficacy and safety of
risankizumab in participants with moderately to severely active
ulcerative colitis. ClinicalTrials.gov. Updated March 10, 2023. Accessed September 26, 2023.
https://clinicaltrials.gov/ct2/show/record/NCT03398148
- SKYRIZI [package insert]. North
Chicago, IL: AbbVie Inc.; 2022.
- Pipeline – Our Science | AbbVie. 2023. Available at:
https://www.abbvie.com/our-science/pipeline.html. Accessed on
September 26, 2023.
- RINVOQ [Package Insert]. North
Chicago, IL: AbbVie Inc.; 2023.
- A Study Comparing Upadacitinib (ABT-494) to Placebo in
Adults With Rheumatoid Arthritis on a Stable Dose of Conventional
Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have
an Inadequate Response to csDMARDs Alone (SELECT-NEXT).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT02675426. Accessed on
September 26, 2023.
- Evaluation of Upadacitinib in Adolescent and Adult
Patients With Moderate to Severe Atopic Dermatitis (Eczema)
(Measure Up 1). ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT03569293. Accessed on
September 26, 2023.
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to
Adalimumab in Participants With Psoriatic Arthritis Who Have an
Inadequate Response to at Least One Non-Biologic Disease Modifying
Anti-Rheumatic Drug (SELECT - PsA 1). ClinicalTrials.gov. 2021.
Available at: https://clinicaltrials.gov/ct2/show/NCT03104400.
Accessed on September 26, 2023.
- A Study to Evaluate Efficacy and Safety of Upadacitinib in
Adult Participants With Axial Spondyloarthritis (SELECT AXIS 2).
ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT04169373. Accessed on
September 26, 2023.
- A Study of the Efficacy and Safety of Upadacitinib
(ABT-494) in Participants With Moderately to Severely Active
Crohn's Disease Who Have Inadequately Responded to or Are
Intolerant to Biologic Therapy. ClinicalTrials.gov. 2021. Available
at: https://clinicaltrials.gov/ct2/show/NCT03345836. Accessed on
September 26, 2023.
- A Study to Evaluate the Safety and Efficacy
of Upadacitinib (ABT-494) for Induction and Maintenance
Therapy in Participants With Moderately to Severely Active
Ulcerative Colitis (UC). ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT02819635. Accessed on
September 26, 2023.
- A Study to Evaluate the Safety and Efficacy
of Upadacitinib in Participants With Giant Cell rteritis
(SELECT-GCA). ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT03725202. Accessed on
September 26, 2023.
- A Study to Evaluate the Efficacy and Safety
of Upadacitinib in Subjects With Takayasu Arteritis (TAK)
(SELECT-TAK). ClinicalTrials.gov. 2021. Available at:
https://clinicaltrials.gov/ct2/show/NCT04161898. Accessed on
September 26, 2023.
- A Multicenter, Randomized Open-Label Study to Assess the
Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a
Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18
Years Old With Active Systemic Juvenile Idiopathic Arthritis.
ClinicalTrials.gov. Available at:
https://clinicaltrials.gov/study/NCT05609630?cond=Systemic%20Juvenile%20Idiopathic%20Arthritis&intr=Upadacitinib&rank=1.
Accessed on September 26, 2023.
![AbbVie logo AbbVie logo](https://mma.prnewswire.com/media/386913/AbbVie_logo.jpg)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/abbvie-showcases-breadth-and-depth-of-research-in-crohns-disease-and-ulcerative-colitis-at-ueg-week-2023-301951592.html
SOURCE AbbVie